NFG
SAGE

Next Financial Group’s Sage Therapeutics SAGE Stock Holding History

Next Financial Group’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$0 Buy
+5
New +$209 ﹤0.01% 2956

Other funds holding SAGE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Next Financial Group's SAGE Position: Q4 2021 in Review

Next Financial Group opened a new position in Sage Therapeutics (SAGE) in Q4 2021: 5 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #2956 among its holdings.

216 funds tracked by Wall St. Rank hold SAGE as of Q4 2021.

  • Next Financial Group held 5 shares of Sage Therapeutics worth $0 as of Q4 2021.
  • Sage Therapeutics was a new Next Financial Group position in Q4 2021.
  • Sage Therapeutics made up ﹤0.01% of Next Financial Group's portfolio in Q4 2021, its #2956 holding.
  • 216 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2021.

Based on Next Financial Group's 13F filing for Q4 2021, filed 15 Feb 2022.